Press Releases

GlobeNewswire, Inc.

Company announcement – No. 30 / 2026 Total number of shares and voting rights in Zealand Pharma as of June 30, 2026 Copenhagen, Denmark, June 30, 2026 – Zealand Pharma A/S (“Zealand Pharma” or "the Company") (Nasdaq: ZEAL) (CVR-no. 20045078), a...

GlobeNewswire, Inc.

Company announcement No. 29 / 2026 Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc. Copenhagen, Denmark, June 30, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a...

GlobeNewswire, Inc.

SEATTLE, June 30, 2026 (GLOBE NEWSWIRE) -- Drug developers have a new, optimized option for U.S.-based manufacturing, as AGC Biologics enters a strategic partnership with Pyramid Pharma Services.

GlobeNewswire, Inc.

Company announcement No. 28 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 26, 2026) Copenhagen, Denmark, June 29, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a...

GlobeNewswire, Inc.

COPENHAGEN, Denmark, June 29, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that Health Canada has approved VIMKUNYA® (recombinant, adsorbed) for immunization to prevent disease caused by chikungunya virus infection for individuals 12...

GlobeNewswire, Inc.

LARGO, FL, June 28, 2026 (GLOBE NEWSWIRE) -- JellyFil, a company established in 2026, today announced its entry into the men's wellness supplement category with the introduction of its first product, JellyFil. The launch marks the company's...

GlobeNewswire, Inc.

DUBLIN, Ireland and BRIDGEWATER, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, applauds the recent FDA approval of injectable...

GlobeNewswire, Inc.

New results from HMB-002 first-in-human data validate proof of mechanism in Von Willebrand disease (VWD), elevating Von Willebrand Factor (VWF) and Factor VIII (FVIII) levels with subcutaneous dosing; multiple dose assessment underway New program...

GlobeNewswire, Inc.

Data presented during ICCBH 2026 showed that improvements in tibial-femoral angle (TFA), a measure of lower extremity alignment, continued through Week 104 Greater improvements observed in children with preexisting genu varum (leg bowing)...

GlobeNewswire, Inc.

AUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- ESO Solutions, Inc. (“ESO”), a leading data services and software provider for EMS, fire departments, hospitals, and government agencies, today announced the launch of ESO Prehospital Intelligence™,...

GlobeNewswire, Inc.

Advanced analytical methods integrating clinical trial and real-world data address key evidence gaps in rare, difficult-to-treat blood cancers Across both studies, mogamulizumab was associated with improved survival outcomes compared to standard...

GlobeNewswire, Inc.

LAKELAND, FL, June 23, 2026 (GLOBE NEWSWIRE) -- JellyFil, a newly established company in the men's wellness sector, today announced the launch of JellyFil, a dietary supplement formulated to support men's energy, stamina, libido, and overall...

GlobeNewswire, Inc.

Company announcement – No. 27 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, June 22, 2026 – Zealand Pharma A/S...

GlobeNewswire, Inc.

Key U.S. patent now protects exclusivity for developing stenoparib with the stenoparib-DRP® until April 2042 TARPON SPRINGS, Fla., June 30, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage...

GlobeNewswire, Inc.

Company announcement No. 26 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 25, 2026) Copenhagen, Denmark, June 22, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a...

EIN Presswire

Non-Alcoholic Beer Market is segmented by product type, distribution channel, packaging, flavor profile, and region.

EIN Presswire

Amid Record-Breaking Fatalities of World’s Journalists, Good Tape introduces the “Names” Awareness Campaign and Critical Support for Front-line Media Workers.

GlobeNewswire, Inc.

COPENHAGEN, Denmark, June 19, 2026 (GLOBE NEWSWIRE) -- The Novo Nordisk Foundation is funding a new pan-European initiative to accelerate drug discovery and the development of next generation therapeutics for cardiometabolic diseases (CMDs). The...

GlobeNewswire, Inc.

Company Announcement Topline results from Phase 3 EPCORE® DLBCL-4 evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients...

GlobeNewswire, Inc.

Pharmaceutical executive and physician with strong experience in global research and development Over 20 years’ experience in all stages of clinical development across multiple indications, including neurology and psychiatry programs Appointment...